Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma

Wen-Juan Liu1, Kun-Li Zhu2, Jian Xu3

  • 1Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, 250117, China.

Insights

A novel fusion protein, Ec-LDP(AE)-DF, targets lung cancer cells by leveraging human beta-defensin-1 and an EGFR-targeting peptide. This potent agent induces apoptosis and inhibits tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Human beta-defensins (HBDs) possess oncolytic properties, with a fragment of HBD1 (DF) showing antitumor effects.
  • Targeted drug delivery using fusion proteins can enhance therapeutic efficacy, but this approach has not been explored for HBDs.
  • Epidermal growth factor receptor (EGFR) is a validated target in non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To design and synthesize a novel fusion protein incorporating an HBD1 fragment (DF), an EGFR-targeting oligopeptide (Ec), and lidamycin (LDM).
  • To evaluate the efficacy and mechanism of action of the fusion protein, particularly its enediyne-integrated analog (Ec-LDP(AE)-DF), against NSCLC.
  • To assess the potential of Ec-LDP(AE)-DF as a targeted therapeutic agent for NSCLC.

Main Methods:

  • Construction and purification of fusion proteins: Ec-LDP-DF and Ec-LDP(AE)-DF.
  • In vitro studies: Cytotoxicity assays on NSCLC cell lines, cell cycle analysis, apoptosis induction, and assessment of EGFR phosphorylation.
  • In vivo studies: Treatment of human lung carcinoma xenografts in athymic mice to evaluate tumor growth inhibition and tolerability.

Main Results:

  • The fusion protein Ec-LDP-DF effectively bound to EGFR-expressing tumor cells.
  • The enediyne-energized fusion protein Ec-LDP(AE)-DF demonstrated extremely potent cytotoxicity against NSCLC cell lines (IC50 < 10-10 M).
  • Ec-LDP(AE)-DF significantly inhibited xenograft tumor growth in mice at well-tolerated doses, inducing cell cycle arrest and apoptosis in a dose-dependent manner, and abolished EGF-stimulated EGFR phosphorylation.

Conclusions:

  • The novel fusion protein Ec-LDP(AE)-DF is a highly potent and targeted therapeutic agent for NSCLC.
  • This agent effectively inhibits tumor growth by inducing cell cycle arrest and apoptosis and by targeting EGFR signaling.
  • Ec-LDP(AE)-DF represents a promising new strategy for NSCLC treatment, building upon the oncolytic potential of defensins.

Related Concept Videos

Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.1K
Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
230
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K
Techniques of therapeutic communication I: Active Listening, Sharing Observations, Validation, and Using Touch01:15

Techniques of therapeutic communication I: Active Listening, Sharing Observations, Validation, and Using Touch

The history of therapeutic communication can be traced back to Florence Nightingale, who emphasized the importance of developing trusting relationships with patients. She taught that the presence of nurses with patients results in therapeutic healing.
Therapeutic communication is not the same as social interaction. Social interaction has no goal or purpose and consists of casual information sharing, whereas therapeutic communication has a plan or purpose for the conversation. Therapeutic...
7.8K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K